U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122024) titled 'Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment' on June 03.
Brief Summary: This is an open-label, randomized controlled study. The study plans to enroll 414 subjects with Helicobacter pylori infection, who will be randomly assigned to the experimental group (Keverprazan dual therapy for 10 days or Keverprazan dual therapy for 14 days) or the control group (Rabeprazole quadruple therapy for 14 days) at a ratio of 1:1:1.
Study Start Date: Feb. 19, 2024
Study Type: INTERVENTIONAL
Condition:
Helicobacter Pylori
Intervention:
DRUG: Keverprazan 10 days
Keverprazan dual thera...